Alkermes Q1 2025 revenue $306.5M, GAAP EPS $0.13; reaffirms 2025 guidance

Alkermes plc.

2025-Q1 EPS reported $0.13 revenue$306,510,000

Total revenues $306.5M, down from $350.4M in Q1 2024; GAAP net income $22.5M ($0.13 diluted EPS).
Proprietary net sales $244.5M (+5% YoY); LYBALVI grew 23% to $70.0M, VIVITROL $101.0M, ARISTADA $73.5M.
Cash and investments $916.2M, up from $824.8M at Dec. 31, 2024.
ALKS 2680 phase 2 Vibrance-1 enrollment complete; topline data expected early Q3 2025.
Company reiterates full-year 2025 financial expectations as communicated Feb. 12, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.